Polyplus secures Warburg Pincus investment
Polyplus-transfection (Polyplus), a developer of cost-effective technology used in gene and cell therapy, has closed on a major investment from Warburg Pincus, a global private equity firm focused on growth investing. Warburg Pincus’ investment alongside the existing majority shareholder, European private equity healthcare specialist ArchiMed, will advance the development and sale

